Attr, Pfizer and BridgeBio
Look out, Pfizer: BridgeBio scores 'best-case' FDA nod for Attruby in cardiomyopathy
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the New York Yankees rallying to win the World Series as they trailed the Los | The FDA has signed off on BridgeBio's Attruby (acoramidis),
BridgeBio poised to challenge Pfizer after Attruby approval
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, BridgeBio has said it will provide Attruby for free for the lifetime of any patient who participated in clinical trials of the drug.
BridgeBio Pharma Gets FDA Approval for Heart Disease Drug Attruby
The Palo Alto, California-based biopharmaceutical company said the Food and Drug Administration approved Attruby for adults with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce cardiovascular death and cardiovascular-related hospitalization.
Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...
After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...
Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.
5don MSN
Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...
Pfizer has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, ...
The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...
Pfizer Inc. named oncology chief Chris Boshoff as its new chief scientific officer on Wednesday, replacing Mikael Dolsten ...
A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...
"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...
Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback